Effects of fish oil supplements in NIDDM subjects. Controlled study
| Autor: | Paresh Dandona, Daniel Wagaine-Twabwe, John S Yudkin, TJ Hendra, Andy Haines, David R Roper, J.Y. Jeremy, ME Britton |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Docosahexaenoic Acids Endocrinology Diabetes and Metabolism Blood lipids Blood sugar chemistry.chemical_compound Fish Oils Internal medicine Diet Diabetic Fatty Acids Omega-3 Internal Medicine Medicine Humans Hemostatic function Triglycerides Advanced and Specialized Nursing Clotting factor Hemostasis business.industry Hypertriglyceridemia medicine.disease Fish oil Eicosapentaenoic acid Lipids Thromboxane B2 Drug Combinations Endocrinology Cholesterol chemistry Diabetes Mellitus Type 2 Eicosapentaenoic Acid Cardiovascular Diseases Food Fortified Female business Diabetic Angiopathies |
| Zdroj: | Diabetes care. 13(8) |
| ISSN: | 0149-5992 |
| Popis: | The aim of this study was to evaluate the effects of a fish oil preparation (MaxEPA) on hemostatic function and fasting lipid and glucose levels in non-insulin-dependent diabetic (NIDDM) subjects. Eighty NIDDM outpatients aged 55.9 yr (mean SD 11.5 yr) participated in a prospective double-blind placebo-controlled study of MaxEPA capsules (10 g/day) or olive oil (control) treatment over 6 wk. Patients received either MaxEPA or olive oil in addition to preexisting therapy. Metabolic and hemostatic variables were measured before treatment and after 3 and 6 wk. Platelet membrane eicosapentaenoic acid (EPA) content increased in the treatment group (P < 0.001). MaxEPA supplementation was associated with a significant fall in total triglycerides (P < 0.001) but did not affect total cholesterol (P = 0.7) compared with control treatment. Fasting plasma glucose increased after 3 wk (P = 0.01) but not after 6 wk (P = 0.17) treatment with MaxEPA. Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P < 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma P-thromboglobulin and platelet factor IV levels. An increase in clotting factor VII (P = 0.02), without changes in fibrinogen or factor X levels, occurred in the MaxEPA group. Similar reductions in blood pressure were observed in both groups. Dietary supplementation with MaxEPA capsules (10 g/day) in NIDDM subjects is associated with improvement in hypertriglyceridemia but with deleterious effects in factor VII and blood glucose levels. Most indices of platelet function are unaffected by this therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|